

Docket No. QUIG-1006US**PATENT****REMARKS**


This amendment is in further response to the Final Rejection dated June 4, 2003 and to a telephone conversation with Examiner Hui on October 21, 2003. The specification and claim 1 are amended herein. No new claims are added. Claims 1 and 3-10 will be pending in the present application upon entry of the amendments herein.

All of the amendments proposed herein are proposed for the purpose of reaching an agreement on allowable subject matter with the Examiner, as discussed during the October 21, 2003 telephone call. Thus entry of the amendments for the purpose of placing the application in condition for allowance, is requested.

Specifically, the language of claim 1 requiring, "compounds that are converted or metabolized into vitamin D₃ in the human body, metabolites thereof" has been replaced by the compound, "1,25-dihydroxyvitamin D₃" found on page 6, line 3 of the specification, at the suggestion of the Examiner. Also, the specification has been amended to insert designations to indicate that certain materials mentioned on pages 11 and 15 were trademarks.

Favorable consideration, entry of the amendments and issuance of a Notice of Allowance are requested.

Respectfully submitted,


Kevin J. Dunleavy
Registration No. 32,024

Dated: October 22, 2003

KNOBLE & YOSHIDA, LLC (Customer No. 21,302)
Eight Penn Center, Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Direct Dial No.: (215) 599-0606
Facsimile No.: (215) 599-0601
e-mail: kjdunleavy@patentwise.com

**RECEIVED
CENTRAL FAX CENTER
OCT 22 2003**

[Faint handwritten initials]